Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Domchek

Showing results (71-80 of 94) with videos related to

Pageof 10
Sort By:
Gynecologic Oncology|October 8, 2021
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancerPayal D Shah, Stephanie L Wethington, Cheyenne Pagan, et al.
Journal of Medical Genetics|April 10, 2019
Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA reportAmanda B Spurdle, Stephanie Greville-Heygate, Antonis C Antoniou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response DefectsSami Belhadj, Aliya Khurram, Chaitanya Bandlamudi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 29, 2011
Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen, Sean Brummel, Yuan Chun Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related GenesNadine M Tung, Mark E Robson, Steffen Ventz, et al.
Cancer Discovery|September 23, 2016
A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast CancerJoseph Vijai, Sabine Topka, Danylo Villano, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 7, 2011
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal statusSteven J Skates, Phuong Mai, Nora K Horick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.
British Journal of Cancer|June 26, 2008
Rapid progression of prostate cancer in men with a BRCA2 mutationS A Narod, S Neuhausen, G Vichodez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
Pageof 10

Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Gynecologic Oncology|October 8, 2021
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancerPayal D Shah, Stephanie L Wethington, Cheyenne Pagan, et al.
Journal of Medical Genetics|April 10, 2019
Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA reportAmanda B Spurdle, Stephanie Greville-Heygate, Antonis C Antoniou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
NBN Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and In Vitro DNA Damage Response DefectsSami Belhadj, Aliya Khurram, Chaitanya Bandlamudi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 29, 2011
Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen, Sean Brummel, Yuan Chun Ding, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related GenesNadine M Tung, Mark E Robson, Steffen Ventz, et al.
Cancer Discovery|September 23, 2016
A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast CancerJoseph Vijai, Sabine Topka, Danylo Villano, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 7, 2011
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal statusSteven J Skates, Phuong Mai, Nora K Horick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.
British Journal of Cancer|June 26, 2008
Rapid progression of prostate cancer in men with a BRCA2 mutationS A Narod, S Neuhausen, G Vichodez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening TrialsSteven J Skates, Mark H Greene, Saundra S Buys, et al.
Pageof 10